Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia

Given its myeloid‐restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Bras, Anne E., Osmani, Zgjim, de Haas, Valerie, Jongen‐Lavrencic, Mojca, te Marvelde, Jeroen G., Zwaan, C. Michel, Mejstrikova, Ester, Fernandez, Paula, Szczepanski, Tomasz, Orfao, Alberto, van Dongen, Jacques J. M., van der Velden, Vincent H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247412/
https://www.ncbi.nlm.nih.gov/pubmed/33161592
http://dx.doi.org/10.1111/bjh.17210
Descripción
Sumario:Given its myeloid‐restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte‐based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.

Ejemplares similares